APO RESEARCH · REPORT
Glucagon Like Peptide-1 (GLP-1) Agonists
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
Product & engineering
Understand the product.
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
Selected research
Industry Research
Glucagon Like Peptide-1 (GLP-1) Agonists Industry Research Report 2026
Market perspective
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry by 68% market shares.
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44%. The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28%.
Read the full market overview
Report Scope
This report quantifies the global Glucagon Like Peptide-1 (GLP-1) Agonists market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Glucagon Like Peptide-1 (GLP-1) Agonists Market by Company
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Amylin
Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Type
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Application
Hospital
Pharmacy
Other
Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glucagon Like Peptide-1 (GLP-1) Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Glucagon Like Peptide-1 (GLP-1) Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glucagon Like Peptide-1 (GLP-1) Agonists.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Glucagon Like Peptide-1 (GLP-1) Agonists manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Glucagon Like Peptide-1 (GLP-1) Agonists by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Glucagon Like Peptide-1 (GLP-1) Agonists in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Exenatied
- Liraglutide
- Lixisenatide
- Albiglutide
- Dulaglutide
Applications
- Hospital
- Pharmacy
- Other
Companies covered
- Novo Nordisk
- AstraZeneca
- Eli Lily
- GSK
- Sanofi
- Bristol-Myers Squibb
- Amylin
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size (2021-2032)
- 2.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (2021-2032)
- 2.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Average Price (2021-2032)
- 2.3 Glucagon Like Peptide-1 (GLP-1) Agonists by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Exenatied
- 2.3.3 Liraglutide
- 2.3.4 Lixisenatide
- 2.3.5 Albiglutide
- 2.3.6 Dulaglutide
- 2.4 Glucagon Like Peptide-1 (GLP-1) Agonists by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Pharmacy
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue of Manufacturers (2021-2026)
- 3.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Manufacturers (2021-2026)
- 3.5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Product Type & Application
- 3.8 Global Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Established Date
- 3.9 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novo Nordisk
- 4.1.1 Novo Nordisk Company Information
- 4.1.2 Novo Nordisk Business Overview
- 4.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
- 4.1.5 Novo Nordisk Recent Developments
- 4.2 AstraZeneca
- 4.2.1 AstraZeneca Company Information
- 4.2.2 AstraZeneca Business Overview
- 4.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
- 4.2.5 AstraZeneca Recent Developments
- 4.3 Eli Lily
- 4.3.1 Eli Lily Company Information
- 4.3.2 Eli Lily Business Overview
- 4.3.3 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
- 4.3.5 Eli Lily Recent Developments
- 4.4 GSK
- 4.4.1 GSK Company Information
- 4.4.2 GSK Business Overview
- 4.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
- 4.4.5 GSK Recent Developments
- 4.5 Sanofi
- 4.5.1 Sanofi Company Information
- 4.5.2 Sanofi Business Overview
- 4.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
- 4.5.5 Sanofi Recent Developments
- 4.6 Bristol-Myers Squibb
- 4.6.1 Bristol-Myers Squibb Company Information
- 4.6.2 Bristol-Myers Squibb Business Overview
- 4.6.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
- 4.6.5 Bristol-Myers Squibb Recent Developments
- 4.7 Amylin
- 4.7.1 Amylin Company Information
- 4.7.2 Amylin Business Overview
- 4.7.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
- 4.7.5 Amylin Recent Developments
5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Scenario by Region
- 5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2021-2032
- 5.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2021-2026
- 5.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2027-2032
- 5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region: 2021-2032
- 5.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region: 2021-2026
- 5.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region: 2027-2032
- 5.4 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
- 5.4.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2032)
- 5.4.3 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
- 5.5.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2032)
- 5.5.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
- 5.6.1 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
- 5.7.1 South America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2032)
- 5.7.3 South America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2032)
- 6.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2021-2032)
- 6.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021-2032)
- 6.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2021-2032)
- 6.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2032)
- 7.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2021-2032)
- 7.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021-2032)
- 7.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2021-2032)
- 7.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Glucagon Like Peptide-1 (GLP-1) Agonists Value Chain Analysis
- 8.1.1 Glucagon Like Peptide-1 (GLP-1) Agonists Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Glucagon Like Peptide-1 (GLP-1) Agonists Production Mode & Process
- 8.2 Glucagon Like Peptide-1 (GLP-1) Agonists Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Distributors
- 8.2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Customers
9 Global Glucagon Like Peptide-1 (GLP-1) Agonists Analyzing Market Dynamics
- 9.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends
- 9.2 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Drivers
- 9.3 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Opportunities and Challenges
- 9.4 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst